Computational Design Boosts Melanoma Inhibitor Peptide's Anticancer Potency

Melanoma is an aggressive form of skin cancer with high mortality rates, often characterized by resistance to conventional therapies. A key mechanism of cancer cell survival involves the overexpression of Inhibitor of Apoptosis Proteins (IAPs), which block programmed cell death (apoptosis). The Melanoma Inhibitor of Apoptosis (ML-IAP) peptide is a promising therapeutic target, but its efficacy can be limited by stability and binding affinity. This study addresses the critical need to enhance the therapeutic properties of ML-IAP through advanced computational engineering.

The computational screening successfully identified three lead ML-IAP peptide variants with significantly improved properties compared to the wild-type peptide. Specifically, variant ML-IAP-V3 demonstrated a remarkable 2.5-fold increase in binding affinity to XIAP, with a predicted Ki (inhibition constant) of 0.5 nM compared to 1.25 nM for the original peptide. This enhanced affinity suggests a more potent inhibition of cancer cell survival pathways. The most promising variant, ML-IAP-V3, showed a 43% reduction in predicted proteolytic degradation over a simulated 24-hour period in plasma-like conditions, indicating substantially improved stability. Furthermore, molecular dynamics simulations predicted that ML-IAP-V3 maintained its active, functional conformation for 90% longer than the original peptide, suggesting a more sustained therapeutic effect. The engineered peptides also exhibited a 30% lower predicted off-target binding risk to non-apoptotic proteins, enhancing specificity.